Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-1200 |
Synonyms | |
Therapy Description |
Limited information is currently available on MK-1200, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Mar 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-1200 | MK1200|MK 1200 | Limited information is currently available on MK-1200, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Mar 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06242691 | Phase II | MK-1200 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | ISR | AUS | 3 |